8-K: Xilio Therapeutics Secures $50 Million in Public Offering to Extend Cash Runway Through Q3 2026

Xilio Therapeutics, a clinical-stage biotechnology company, announced the pricing of a $50.0 million public offering of pre-funded and common stock warrants, aiming to extend its cash runway through the third quarter of 2026.

Summary

• Xilio Therapeutics, Inc. has priced an underwritten public offering of pre-funded warrants and three series of common stock warrants (Series A, Series B, and Series C).
• The offering includes 66,676,000 pre-funded warrants, 66,676,000 Series A warrants, 66,676,000 Series B warrants, and 66,676,000 Series C warrants.
• The combined public offering price for one pre-funded warrant and accompanying common warrants is $0.7499.
• The pre-funded warrants have an exercise price of $0.0001 per share, while the Series A, B, and C warrants have an exercise price of $0.75 per share.
• The Company estimates net proceeds from the offering to be approximately $46.6 million, after deducting underwriting discounts and commissions and estimated offering expenses, and excluding proceeds from warrant exercises.
• If all Series B and Series C warrants are exercised in cash at their exercise price, the Company could receive an additional gross proceeds of approximately $100.0 million.
• The proceeds are intended to advance the development of product candidates, for working capital requirements, and other general corporate purposes.
• Exercisability of the warrants is subject to limitations, including stockholder approval for an increase in authorized common stock and beneficial ownership caps (4.99% or up to 19.99% at holder's election).
• Series B and C warrants are subject to offset and cancellation on a dollar-for-dollar basis against non-dilutive capital (e.g., milestone payments, option fees, certain equity issuances above $1.50/share) if such capital totals at least $20 million.
• Future equity issuances by the Company until December 1, 2026, or until all Series B and C warrants are exercised/expired, will be subject to a minimum purchase price of $1.50 per share, which can be waived by majority Series B/C warrant holders or reduced to $1.00 per share if a majority of pre-funded warrants are exercised by December 1, 2025.

Sentiment

Score: 6

Explanation: The capital raise is crucial for Xilio Therapeutics, providing immediate funds and extending the cash runway, which is positive for a clinical-stage biotech. However, the significant potential dilution from the warrants and the contingencies surrounding their full exercisability (stockholder approval, beneficial ownership limits, and offset clauses) introduce notable uncertainties and potential downsides for existing shareholders and warrant holders.

Positives

• The offering provides immediate net proceeds of approximately $46.6 million, bolstering the Company's financial position.
• The Company projects that these proceeds, combined with existing cash, will extend its cash runway through the end of the third quarter of 2026, providing critical funding for ongoing operations and product development.
• The potential for an additional $100.0 million in gross proceeds from the exercise of Series B and C warrants offers significant future capital infusion opportunities.
• The offering is underwritten by Leerink Partners LLC, indicating institutional confidence in the Company's prospects.

Negatives

• The offering involves a substantial number of warrants (66,676,000 for each of four types), indicating significant potential future dilution for existing shareholders upon exercise.
• The full exercisability of the warrants is contingent on stockholder approval to increase the number of authorized common stock shares, introducing uncertainty and potential delays.
• Series B and C warrants are subject to offset and cancellation based on the Company receiving non-dilutive capital, which could reduce their value for holders without compensation.
• There is no guarantee that the common stock warrants will be exercised for cash or at all, meaning the potential $100.0 million in additional gross proceeds may not materialize.
• The minimum purchase price for future equity issuances can be waived or reduced, potentially leading to further dilutive capital raises at lower prices.

Risks

• **Authorized Share Failure**: The Company currently lacks sufficient authorized shares to issue all Warrant Shares upon exercise, requiring stockholder approval for an increase. Failure to obtain this approval could limit exercisability or necessitate cash settlement for Series B warrants.
• **Warrant Exercise Uncertainty**: There is no assurance that any of the common stock warrants will be exercised for cash or at all, which means the potential additional $100.0 million in gross proceeds may not be realized.
• **Dilution**: The issuance of a large number of warrants and underlying shares could significantly dilute the ownership percentage and value for existing shareholders.
• **Cash Runway Assumptions**: The Company's cash runway estimate through Q3 2026 is based on assumptions that may prove incorrect, potentially leading to the exhaustion of available capital resources sooner than anticipated.
• **Market Conditions**: General economic, industry, or political conditions in the U.S. or internationally could adversely impact the offering, the Company's stock price, and its operations.
• **Future Equity Issuance Price**: The minimum price floor for future equity issuances can be waived or reduced, potentially exposing the Company to more dilutive capital raises at lower prices in the future.

Future Outlook

Xilio Therapeutics estimates that its existing cash and cash equivalents, combined with the $46.6 million net proceeds from this public offering (excluding potential payments from existing collaboration and partnership agreements), will enable the Company to fund its operating expenses and capital expenditure requirements through the end of the third quarter of 2026. The Company cautions that this estimate is based on assumptions that may prove incorrect, and available capital resources could be exhausted sooner than anticipated.

Management Comments

• "Xilio intends to use the net proceeds received from the offering to advance the development of its product candidates and for working capital requirements and other general corporate purposes."

Industry Context

This capital raise by Xilio Therapeutics is a common financing strategy for clinical-stage biotechnology companies, which typically require significant capital to fund research, development, and clinical trials for their product candidates. The use of a combination of pre-funded and common stock warrants allows the company to secure immediate funding while offering investors additional upside potential and providing a mechanism for future capital infusions upon warrant exercise. The structured nature of the warrants, including beneficial ownership limits and conditions for exercisability, reflects typical investor protections and regulatory considerations in such specialized financings within the biotech sector.

Comparison to Industry Standards

• The use of pre-funded warrants alongside common stock warrants (Series A, B, C) is a recognized financing structure in the biotechnology industry, often employed by companies like Xilio Therapeutics to raise capital efficiently while managing immediate dilution and offering investors a structured investment vehicle.
• The exercise prices ($0.0001 for pre-funded, $0.75 for common warrants) and varying expiration dates (e.g., Series A expiring in 2030, Series B/C in 2025/2026) are within the typical range for such instruments in biotech financings, often tailored to market conditions and the company's development timeline.
• Beneficial ownership limitations (e.g., 4.99% or 19.99%) are standard provisions in warrant agreements to prevent immediate change of control triggers and to help investors manage their Section 13(d) and Section 16 reporting obligations under the Exchange Act, similar to agreements seen with other biotech firms like Moderna (MRNA) or BioNTech (BNTX) in their early-stage financings, though specific percentages vary.
• The requirement for stockholder approval to increase authorized shares is a common corporate governance step for growth-stage companies, including many in the biotech space, when their current authorized share count is insufficient to cover potential future issuances, as observed in filings from companies like Editas Medicine (EDIT) or CRISPR Therapeutics (CRSP) during their growth phases.
• The 'Minimum Price Floor' for future equity issuances and the 'offset and cancellation' clause for Series B/C warrants based on non-dilutive capital are less common but can be found in highly structured financings, potentially as a mechanism to protect investors from excessive dilution or to incentivize the company to secure non-dilutive funding, though direct comparable examples are less frequent due to the bespoke nature of such clauses.

Corporate Governance

Stakeholder Impact

• **Shareholders**: Face potential significant dilution due to the large number of warrants and underlying shares. However, the capital raise provides essential funding for the Company's operations and product development, which could support long-term value if successful.
• **Warrant Holders**: Gain the opportunity for upside if the Company's stock price increases above the warrant exercise prices. Their exercisability is subject to beneficial ownership limits and the Company's ability to increase authorized shares. Series B and C warrant holders also face the risk of offset/cancellation based on the Company's non-dilutive capital receipts.
• **Company Operations**: The influx of capital significantly extends the Company's cash runway, enabling continued advancement of its product candidates and supporting general corporate purposes, which is vital for a clinical-stage biotechnology firm.

Next Steps

• The closing of the public offering is expected to take place on or about June 5, 2025.
• The Company is required to hold a meeting of its stockholders for the approval of an increase in the number of authorized shares of Common Stock as soon as practicable, but no later than 180 days following the Original Issue Date (October 31, 2025).
• If stockholder approval for the increase in authorized shares is not obtained by October 31, 2025, the Company shall cause an additional stockholder meeting to be held every 180 calendar days thereafter until approval is obtained.
• Following stockholder approval of the Stockholder Resolution, the Company shall amend its certificate of incorporation to effect the increase to its authorized shares.
• The Company is obligated to maintain a registration statement covering the issue and sale of Warrant Shares upon exercise of the Warrants.
• The Company will pay a fee equal to 6.0% of aggregate cash proceeds received from Common Warrant exercises to the Underwriters, no later than three business days following the end of each calendar quarter.

Key Dates

Recommendation

Keywords

Xilio Therapeutics, XLO, public offering, pre-funded warrants, common stock warrants, Series A warrants, Series B warrants, Series C warrants, capital raise, biotechnology, immuno-oncology, SEC filing, Form 8-K, cash runway, dilution, underwriting agreement, Nasdaq